148 related articles for article (PubMed ID: 20624131)
21. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
[TBL] [Abstract][Full Text] [Related]
22. Vigabatrin.
Lewis H; Wallace SJ
Dev Med Child Neurol; 2001 Dec; 43(12):833-5. PubMed ID: 11769271
[No Abstract] [Full Text] [Related]
23. [Changes in visual field of a child treatment with vigabatrin for 2 years].
Mrugacz M; Bakunowicz-Łazarczyk A
Klin Oczna; 2003; 105(5):313-4. PubMed ID: 14746187
[TBL] [Abstract][Full Text] [Related]
24. Steroids or vigabatrin in the treatment of infantile spasms?
Riikonen RS
Pediatr Neurol; 2000 Nov; 23(5):403-8. PubMed ID: 11118795
[TBL] [Abstract][Full Text] [Related]
25. Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry.
Pellock JM; Faught E; Foroozan R; Sergott RC; Shields WD; Ziemann A; Lee D; Dribinsky Y; Torri S; Othman F; Isojarvi J
Epilepsy Behav; 2016 Jul; 60():174-180. PubMed ID: 27208827
[TBL] [Abstract][Full Text] [Related]
26. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval.
Tolman JA; Faulkner MA
Expert Opin Pharmacother; 2009 Dec; 10(18):3077-89. PubMed ID: 19954276
[TBL] [Abstract][Full Text] [Related]
27. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study.
Riikonen R; Rener-Primec Z; Carmant L; Dorofeeva M; Hollody K; Szabo I; Krajnc BS; Wohlrab G; Sorri I
Dev Med Child Neurol; 2015 Jan; 57(1):60-7. PubMed ID: 25145415
[TBL] [Abstract][Full Text] [Related]
28. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile.
Camposano SE; Major P; Halpern E; Thiele EA
Epilepsia; 2008 Jul; 49(7):1186-91. PubMed ID: 18479386
[TBL] [Abstract][Full Text] [Related]
29. Binasal visual field defects are not specific to vigabatrin.
Gonzalez P; Sills GJ; Parks S; Kelly K; Stephen LJ; Keating D; Dutton GN; Brodie MJ
Epilepsy Behav; 2009 Nov; 16(3):521-6. PubMed ID: 19815465
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.
Maguire MJ; Hemming K; Wild JM; Hutton JL; Marson AG
Epilepsia; 2010 Dec; 51(12):2423-31. PubMed ID: 21070215
[TBL] [Abstract][Full Text] [Related]
31. Objective Derivation of the Morphology and Staging of Visual Field Loss Associated with Long-Term Vigabatrin Therapy.
Wild JM; Smith PEM; Knupp C
CNS Drugs; 2019 Aug; 33(8):817-829. PubMed ID: 31250314
[TBL] [Abstract][Full Text] [Related]
32. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.
Lux AL; Edwards SW; Hancock E; Johnson AL; Kennedy CR; Newton RW; O'Callaghan FJ; Verity CM; Osborne JP;
Lancet Neurol; 2005 Nov; 4(11):712-7. PubMed ID: 16239177
[TBL] [Abstract][Full Text] [Related]
33. Understanding and interpreting vision safety issues with vigabatrin therapy.
Plant GT; Sergott RC
Acta Neurol Scand Suppl; 2011; (192):57-71. PubMed ID: 22061181
[TBL] [Abstract][Full Text] [Related]
34. [Visual field changes as a side effect of treatment with vigabatrin therapy].
Kobylański P
Neurol Neurochir Pol; 2000; 34(3):597-9. PubMed ID: 10979552
[No Abstract] [Full Text] [Related]
35. Vigabatrin and visual field disorders.
Prescrire Int; 2002 Dec; 11(62):182. PubMed ID: 12472095
[No Abstract] [Full Text] [Related]
36. Visual field defect associated with vigabatrin. Many more patients may be affected than were found in study.
Comaish IF; Gorman C; Galloway NR
BMJ; 2000 May; 320(7246):1403; author reply 1404. PubMed ID: 10858054
[No Abstract] [Full Text] [Related]
37. Visual field loss associated with vigabatrin: quantification and relation to dosage.
Hardus P; Verduin WM; Engelsman M; Edelbroek PM; Segers JP; Berendschot TT; Stilma JS
Epilepsia; 2001 Feb; 42(2):262-7. PubMed ID: 11240600
[TBL] [Abstract][Full Text] [Related]
38. Delayed, rapid visual field loss in a patient after ten years of vigabatrin therapy.
Clayton LM; Duncan JS; Sisodiya SM; Acheson JF
Eye (Lond); 2010 Jan; 24(1):185-6. PubMed ID: 19373265
[No Abstract] [Full Text] [Related]
39. Characteristics of a unique visual field defect attributed to vigabatrin.
Wild JM; Martinez C; Reinshagen G; Harding GF
Epilepsia; 1999 Dec; 40(12):1784-94. PubMed ID: 10612345
[TBL] [Abstract][Full Text] [Related]
40. Vigabatrin: 2008 update.
Willmore LJ; Abelson MB; Ben-Menachem E; Pellock JM; Shields WD
Epilepsia; 2009 Feb; 50(2):163-73. PubMed ID: 19230067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
